[9]. Scirica, B.M., et al., The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial. J Am Coll Cardiol, 2024. 84(17): p. 1632-1642. [10]. Marso, S.P., et al., Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diab...
Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.105...
[2]. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121-130. [3]. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and ...
[9]. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes[J]. N Engl Med, 2016, 375:1834-44. [10]. Kunutsor SK, Zaccardi F,Balasubramanian VG, et al. Glycaemic control and macrovascula...
[1]. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. [2]. Gerstein HC, Colhoun HM, Dagenais GR, et al. D...
图1：CVOT试验概览 2020年ADA年会，来自多伦多大学的Mansoor Husain教授进行了题为GLP-1 Receptor Agonists and Cardiovascular Outcomes—The Evidence的演讲。Mansoor Husain教授对五项基于人GLP-1类似物的CVOT研究进行荟萃分析（共纳入了3.5万人），分析发现人GLP-1类似物可降低17%的主要心血管不良事件（MACE）风险（...
2020年ADA年会,来自多伦多大学的Mansoor Husain教授进行了题为GLP-1 Receptor Agonists and Cardiovascular Outcomes—The Evidence的演讲。Mansoor Husain教授对五项基于人GLP-1类似物的CVOT研究进行荟萃分析(共纳入了3.5万人),分析发现人GLP-1类似物可降低17%的主要心血管不良事件(MACE)风险(VS.SGLT-2i, 11%)(图2...
1.Hertel C Cerstein, Helen M Colhoun, Gilles R Dagenais, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial [J]. Lancet. https://doi.org/10.1016/S0140-6736(19)31149-3 ...
7.H. C. Gerstein, H. M. Colhoun, G. R. Dagenaiset al., Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.Lancet394, 121-130 (2019). 8.H. C. Gerstein, H. M. Colhoun, G. R. Dagenaiset al., Dulaglutide and re...
[3] Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity with...